Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

38.41USD
16 Aug 2019
Change (% chg)

$1.12 (+3.00%)
Prev Close
$37.29
Open
$37.54
Day's High
$38.67
Day's Low
$37.42
Volume
127,630
Avg. Vol
188,797
52-wk High
$60.98
52-wk Low
$36.19

Lalwani, Narendra 

Dr. Narendra D. Lalwani, Ph.D., FAHA, DABT is Executive Vice President - Research & Development of the Company. He was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Dr. Lalwani was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Dr. Lalwani held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Dr. Lalwani is a Fellow of the American Heart Association (FAHA) and a diplomat of the American Board of Toxicology (DABT). Dr. Lalwani earned a Ph.D. in Biophysics from the University of Bombay (India) and an M.B.A from the University of Michigan Ross School of Business.

Basic Compensation

Total Annual Compensation, USD 430,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,915,320
Fiscal Year Total, USD 2,345,320

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Timothy Mayleben

9,724,840

Richard Bartram

2,539,920

Narendra Lalwani

2,345,320

Mark Glickman

9,014,660

Nicole Vitullo

311,662

Jeffrey Berkowitz

1,406,680
As Of  31 Dec 2018